Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10023MR)

This product GTTS-WQ10023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10023MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10028MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ5782MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ2144MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ14095MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ5881MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ6056MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ15194MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ8591MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW